Module 5: Advancing Along the Translational Spectrum: Predictive Models in Drug Development — Pharmacology and Toxicology Testing in the Preclinical Research Project
Module overview
What you will learn
Module 5 highlights the roles of toxicology, pharmacology and pharmacokinetics testing to advance drug discovery and development projects to investigational new drug (IND) status. It also highlights best practices for advancing to IND status.
Lecturers
Udo Rudloff, M.D., Ph.D.
Senior Investigator, Pediatric Oncology Branch, National Cancer Institute
Jessica M. Faupel-Badger, Ph.D., M.P.H.
Director for the Cancer Prevention Fellowship Program, Planning Officer for the Division of Cancer Prevention, National Cancer Institute
Philip E. Sanderson, Ph.D.
Project Leader and Manager, Division of Preclinical Innovation, NCATS
Xin Xu, Ph.D.
Director of Pharmacokinetics, Division of Preclinical Innovation, NCATS
Pramod S. Terse, Ph.D.
Toxicologist, Division of Preclinical Innovation, NCATS
Lectures
Open Opportunities
Selection of Animal Models for Drug Candidates
(video length: 22:24)
Pancreatic Cancer Overview
(video length: 23:57)
Transitioning from Discovery Research to IND Enabling Studies
(video length: 23:25)
Application of Pharmacokinetics in Preclinical Translational Research
(video length: 19:04)
The Role of Safety in Drug Discovery and Development
(video length: 46:32)
Resources
Download materials for this module:
- Module 5 Readings (PDF - 136KB)
- Module 5 Quiz (PDF - 67KB)
 |  | Except where otherwise noted, this work is licensed under https://creativecommons.org/licenses/by/4.0/ |